Bajaj Healthcare Receives NCLT Approval for Genrx Pharmaceuticals Acquisition

NCLT Mumbai approval granted on October 13, 2026. Genrx Pharmaceuticals to become a wholly owned subsidiary.

Reader Takeaway: This inorganic expansion bolsters asset capacity, though investors should watch for integration timelines and operational updates.

What just happened

Bajaj Healthcare Limited has officially received approval from the Hon'ble National Company Law Tribunal (NCLT), Mumbai Bench, to acquire Genrx Pharmaceuticals Private Limited. The order, issued on October 13, 2026, allows Bajaj Healthcare to acquire the entity on a going concern basis. The company confirmed it accessed the formal order via the NCLT portal on the same day.

Why this matters

This acquisition represents a strategic pivot for Bajaj Healthcare as it seeks to expand its footprint in the sector. By transitioning Genrx Pharmaceuticals into a wholly owned subsidiary, Bajaj Healthcare gains control over new assets and potential operational capabilities. For shareholders, this represents a shift toward inorganic growth as the company looks to scale its infrastructure through the acquisition of distressed or available assets.

What happens next

Following this regulatory approval, Bajaj Healthcare will now proceed to implement the specific terms dictated by the NCLT order. This involves the formal legal and operational transition of Genrx into the Bajaj Healthcare fold. Investors should look for future exchange filings detailing the completion of the takeover and any subsequent management guidance regarding how these new assets will be integrated into the company's broader business model.

What to track next

Watch for the formal closing date of the transaction. Additionally, keep an eye on management's future disclosures regarding how they intend to deploy Genrx Pharmaceuticals' assets to drive revenue or operational efficiency in upcoming quarters.